Schizophrenia - A Pipeline Analysis Report

Drug development for schizophrenia

Technavio’s market research analysts have predicted that with the introduction of psycho-education, arts therapies, family therapy, and antipsychotic treatment as some of the most promising approaches to treat schizophrenia, the global schizophrenia market will witness growth in the forthcoming years.

 Get A Free Sample

According to this pipeline analysis report, most of the drug development molecules in the pipeline are under the phase II and pre-clinical development stages. For instance, sponsors such as Athersys developed 5-HT2C and Concert Pharmaceuticals developed CTP-692, which are under pre-clinical development stage. Our market research analysts have also identified that a small amount of drug molecules that are being developed comes under phase II/III, phase I/II, pre-registration, and discovery development stages. The pipeline landscape in the pipeline analysis report mentions the percentage of drug development molecules that are under phase I and phase III stages.

Drug development market: Companies covered

This pipeline analysis report provides a detailed analysis of the companies that are involved in the development of drug molecules for the treatment of schizophrenia. In addition to providing information on the various stages of molecules developed by companies for different indications, this pipeline analysis report also provides information about the drug development molecules discontinued by companies.

Some of the companies covered in this pipeline analysis report are –

• Kowa
• KemPharm
• NeurOp

Therapeutic assessment of the drug development pipeline for schizophrenia by preferred route of administration

• Injection
• Intramuscular injection
• Intravenous
• Oral
• Oral + Subcutaneous
• Subcutaneous
• Transdermal

The oral route of administration (ROA) involves the administration of drug substances through mouth cavity. It has been observed that the majority of total therapeutics are being developed for oral administration.

Therapeutic assessment of the drug development pipeline for schizophrenia by therapeutic modality

• Small molecule
• Undisclosed

According to this pipeline analysis report, the majority of molecules that are currently in the drug development pipeline for schizophrenia are being developed as small molecules. Small molecules are chemically manufactured active substances that are able to enter the cells easily because of their low molecular weight.

Want a bigger picture? Try a FREE sample of this report now!

See the complete table of contents and list of exhibits, as well as selected illustrations and example pages from this report.   

Key questions answered in the report include

• What are the drug development molecules in the various development stages for schizophrenia?
• What are the companies that are currently involved in the development of drug molecules for schizophrenia?
• Insight into discontinued/inactive molecules with appropriate reasoning?
• What are the major regulatory authorities approving drugs in various regions?
• Detailed profiling of each active molecule

Technavio also offers customization on reports based on specific client requirement.